Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence and Booster Response of Menveo in Children
NCT01345721Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Sep 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (3 arms), sponsored by Novartis. Primary endpoints: Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers >= 1:8, Percentage of Subjects With Serum Bactericidal Antibody Titers >= 1:8 One Month After Booster and 1 more. Started May 2011; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01345721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345721.